Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name Lisocabtagene maraleucel
Trade Name Breyanzi
Synonyms JCAR 017|JCAR017|JCAR-017
Drug Descriptions

Breyanzi (lisocabtagene maraleucel) comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may result in immune-modulating and anti-tumor activities (PMID: 32888407). Breyanzi (lisocabtagene maraleucel) is FDA approved for use in patients with large B-cell lymphoma including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who are refractory to or relapsed within 12 months of first-line immunochemotherapy, or have refractory or relapsed disease after first-line immunochemotherapy and not eligible for hematopoietic stem cell transplantation, or have relapsed or refractory disease after two or more lines of systemic therapy, and in patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy (FDA.gov).

DrugClasses CD19 Immune Cell Therapy 62
CAS Registry Number NA
NCIT ID C125192

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Acalabrutinib + Lisocabtagene maraleucel Acalabrutinib Lisocabtagene maraleucel 0 1
axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Lisocabtagene maraleucel Tisagenlecleucel axicabtagene ciloleucel 0 1
Cyclophosphamide + Fludarabine + Ibrutinib + Lisocabtagene maraleucel Cyclophosphamide Fludarabine Ibrutinib Lisocabtagene maraleucel 0 1
Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel Cyclophosphamide Fludarabine Lisocabtagene maraleucel 0 2
Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel + Zanubrutinib Cyclophosphamide Fludarabine Lisocabtagene maraleucel Zanubrutinib 0 1
Durvalumab + Lisocabtagene maraleucel Durvalumab Lisocabtagene maraleucel 0 1
Ibrutinib + Lisocabtagene maraleucel Ibrutinib Lisocabtagene maraleucel 0 1
Lisocabtagene maraleucel Lisocabtagene maraleucel 0 7


Additional content available in CKB BOOST